Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. (NASDAQ: TNON) is a medical device company focused on minimally invasive sacroiliac (SI) joint and sacro-pelvic fusion technologies. News about Tenon often centers on its Catamaran SI Joint Fusion System, the Catamaran SE reduced-profile implant, and the SImmetry and SImmetry+ SI Joint Fusion Systems acquired through the SiVantage transaction. These platforms are designed to stabilize the SI joint and promote true fusion using titanium implants and proprietary instrumentation.
Investors and clinicians following TNON news can expect updates on product clearances, commercial launches and clinical milestones. Recent announcements include FDA 510(k) clearance for the SImmetry+ SI Joint Fusion System, which uses 3D-printed titanium implants and a minimally invasive lateral access approach, and the successful completion of initial clinical cases with SImmetry+ at spine centers across multiple U.S. states. Tenon also reports on the full market launch of the Catamaran SE SI Joint Fusion System, expanding its implant portfolio with a smaller device option for varying anatomy and revision scenarios.
Tenon’s news flow also covers financial performance and capital markets activity. Quarterly earnings releases discuss revenue from Catamaran and SImmetry procedures, gross margin trends, operating expenses, and cash balances, as well as integration progress for acquired assets and commercial expansion. The company has announced at‑the‑market PIPE financings, detailed in both press releases and Form 8‑K filings, describing share and warrant issuances and intended use of proceeds for working capital, product launches, clinical studies and commercial operations.
Corporate updates in TNON news include asset purchase agreements for sacro-pelvic technologies, employment agreements with key commercial and innovation leaders, and governance matters such as annual meeting voting results and equity incentive plan amendments. For readers tracking developments in SI joint fusion devices, Tenon’s news page provides a centralized view of regulatory, clinical, commercial and financing events related to its sacro-pelvic fusion portfolio.
Tenon Medical, Inc. (NASDAQ:TNON) announced plans to release its financial results for Q1 2023, concluding on March 31, 2023, after market close on May 9, 2023. A conference call will follow at 4:30 p.m. Eastern Time to discuss the results, including a Q&A session. Investors can join the call via dial-in numbers: 1-888-886-7786 (USA) or 1-416-764-8658 (International). The audio will be available for playback until May 23, 2023. Tenon Medical focuses on the Catamaran™ SI Joint Fusion System, which offers a less invasive approach to treat sacroiliac disorders. The company is set for a national launch of this system, targeting a significant market opportunity.
Tenon Medical (NASDAQ:TNON) reported a transformative year, concluding with a 423% revenue increase in Q4 2022, totaling $277,000, and a full-year revenue of $691,000, up 332%. Surgical procedures using the Catamaran System surged 386% in Q4 and 361% for the year. Despite these gains, the company reported a gross loss of $(207,000) in Q4 and $(641,000) for 2022. Operating losses jumped to $7.9 million in Q4 and $18.7 million for the year, impacted by a $3.6 million charge related to the termination of a national distribution agreement. Cash reserves stood at $8.6 million as of year-end, supporting ongoing operations.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
